Binghamton University Executive Vice President and Provost Donald Nieman is pleased to announce that Kanneboyina Nagaraju, known as Raju, has been named Dean of the School of Pharmacy and Pharmaceutical Sciences after a search at national scale. He will take up his new duties on May 12.
“Raju is not just a world-class scientist, he is a leader, innovator, strategic thinker and mentor who listens well and inspires people to do their best,” Nieman said. “He has been a key part of the school’s leadership for six years, and over the past year I have watched him deal with difficult situations, prepare the school for a successful ACPE audit visit and foster collegiality and teamwork. Raju is dedicated to the school, passionate about research and teaching pharmacy, and committed to our students. He will be a great Dean.
“Our goal has been to create a research-intensive school that advances pharmaceutical science research and provides students with innovative pharmaceutical education that prepares them to practice at the top of their license,” said President Harvey Stenger. “As an outstanding scientist, Raju is the ideal candidate to lead our School of Pharmacy and Pharmaceutical Sciences in the next phase of its development. He is a distinguished researcher whose discoveries have led to the development of life-enhancing medicines, and he is passionate about training exceptional pharmacists who will provide evidence-based, patient-centered care to diverse populations.
Nagaraju, currently vice-dean of the school, joined the School of Pharmacy faculty as full professor and founding chair of pharmaceutical sciences in 2016. He stepped down as chair in 2021 when he became Vice Dean. He is also acting chair of the Department of Health Outcomes and Administrative Sciences.
“I am honored to accept this position and to help continue to build on the successes already achieved by the School of Pharmacy and Pharmaceutical Sciences in fostering aggressive growth in clinical research and translational science enterprises, and enhancing visibility and national rankings,” Nagaraju said. “As a new pharmacy school, we are competing with over 140 schools at a time of declining enrollment. We must embrace and lead change by integrating pharmacists as essential members of healthcare teams and deliberately sustain our graduates with an emphasis on patient management skills, leadership and critical thinking to better adapt to changing practice environments.
Named a SUNY Empire Innovation Scholar by the State University of New York Board of Trustees in 2017, Nagaraju rose through the academic ranks at George Washington University before coming to Binghamton, starting as an associate professor of pediatrics in 2005. and becoming a full professor. integrative systems biology and pediatrics. He was also Adjunct Professor of Pharmacology at Dalhousie University in Nova Scotia, Canada from 2014 to 2019.
Prior to his tenure at George Washington University, he served as Assistant Professor of Medicine in the Division of Rheumatology at Johns Hopkins University School of Medicine from 1999 to 2005.
Nagaraju held a research position at the Children’s National Medical Center from 2005 to 2016, serving as Associate Director and then Director of the Genetic Medicine Research Center. He was also director of the preclinical phenotyping and drug testing facility at the Genetic Medicine Research Center for 11 years.
As a postdoctoral researcher, he was a Fogarty International Fellow at the National Institutes of Health, working on rare forms of an autoimmune disease called myositis with the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Nagaraju received his bachelor’s degree in Veterinary Science and Animal Husbandry from College of Veterinary Science, Tirupati, Andhra Pradesh, India; his MSc in Veterinary Immunology from the Indian Veterinary Research Institute, Uttar Pradesh, India; and his PhD in Human Immunology from SGPGI of Medical Sciences, Lucknow, Uttar Pradesh, India.
An expert in translational research on autoimmune and genetic muscle diseases, Nagaraju has been funded by the National Institutes of Health, the United States Department of Defense, the Myositis Association and numerous foundations. He holds 10 patents with Eric Hoffman, Associate Dean for Research and Research Development in the School of Pharmacy and Pharmaceutical Sciences, and medicinal chemist John M. McCall, and co-founded ReveraGen Biopharma with them. Their collaboration led to the identification of vamorolone, a potent anti-inflammatory that resembles standard glucocorticoids, but significantly reduces side effects. Vamorolone has received orphan drug status in the United States for the treatment of Duchenne muscular dystrophy, and the FDA is expected to issue an approval decision later this year. Nagaraju also co-founded Agada Biosciences with Hoffman, to facilitate preclinical and clinical drug development services for neuromuscular diseases.
“I look forward to working with Raju after we both assume our new roles this summer,” said new Executive Vice President for Academic Affairs and Provost Donald Hall. “It was a pleasure to meet him when I was on campus recently and I know he will lead SOPPS to even greater national prominence in the future. He is a deeply caring and knowledgeable administrator and will be a key member of my management team. »